Pipetting robot for academic research - 28/08/2024

goodBot GmbH: a third arm for researchers

Repetitive tasks that researchers have to conduct in the lab tend to be tiring and often lead to errors. Precise pipetting is crucial for achieving reproducible results. Automation is underrepresented in research labs and existing pipetting robots are unsuitable for scientists. This is why Dr. Julius Wiener, Tobias Zundel and Oliver Brunner decided to found the company goodBot GmbH and develop a pipetting robot tailored to academic research.

Synthetic immunology is the topic of an article in the “Perspectives” section of the journal “Nature Nanotechnology”. Herein, Heidelberg researchers describe a so-called bottom-up approach that uses the toolbox of nanotechnology and synthetic biology to construct systems from molecular building blocks and specifically equip them with immune functions.

Knowledge of the target structures for the immune cells is a basic prerequisite for the development of personalized cancer immunotherapies. Scientists from the German Cancer Research Center and the NCT Heidelberg are publishing a sensitive method based on mass spectroscopy to identify such tumor-specific "neoepitopes". The analytical method is designed to detect these low abundance protein fragments and requires minimal amounts of…

How are proteins in our cells modified while they are still being synthesized? An international team of researchers from the University of Konstanz, Caltech, and ETH Zurich has deciphered the molecular mechanism of this vital process.

Scientists at the German Cancer Research Center (DKFZ) have developed a completely new vaccination concept. The vaccine is inexpensive and protects mice against almost all cancer-causing HPV types. In addition to preventing new infections, the vaccine also triggers cellular immune responses against HPV-infected cells and may therefore also have a therapeutic effect against existing infections.

A cutting-edge chemical process is the first to make it possible to quickly and easily produce modified peptides with boronic acids. As part of this work, scientists managed to synthesize a large number of different biologically active peptide boronic acids and investigate their properties. They open up new possibilities in the young research field of synthetic immunology and could go on to be used primarily in immunotherapy.

Start-up Cerebri GmbH - 05/08/2024

Comprehensive EEG supply thanks to telemedicine

Fewer and fewer patients are getting timely access to electroencephalograms, as the process of measuring brain activity and interpreting the results requires specific expertise. Cerebri GmbH, a newly established Tübingen-based company, aims to address this issue by offering user-friendly EEG caps and providing rapid, location-independent and top-tier diagnostics by experts.

Encouraging results from a large international study led by Heidelberg have recently been published in the journal “Lancet”: The genetic material of cancer cells with unknown tissue of origin contains numerous targets for specific drugs that are already available and have been developed to treat other forms of cancer. These suppressed the disease in CUP patients for significantly longer than chemotherapy.

The start of a transnational cooperation for a future of sustainable healthcare - 25/07/2024

BIOPRO is a sustainability partner in the EU HACK-IT-NET project

The HACK-IT-NET (“Health And Care Knowledge and Innovation Transfer NETwork”) project aims to provide holistic and seamless healthcare for all patients in the Alpine region. The project, which was launched in July 2024 and will run for three years, aims to bring together stakeholders in the healthcare sector to create a forward-looking healthcare ecosystem in the Alpine region. BIOPRO is a partner.

Research association - 24/07/2024

SPI-MP: pioneer in personalised medical technology

Every person is unique – even when they are ill. This is why many approaches to personalised medicine have been under development. The Stuttgart Partnership Initiative - Mass Personalization (SPI-MP), which focuses on basic research into fabrication and biomaterial technologies for personalised biomedical systems, is at the heart of such research work. The projects range from artificial knee joint cartilage to state-of-the-art stroke diagnostics.

The "Friends of the German Cancer Research Center" association supports the DKFZ and aims to help strengthen its position in international competition. With the DKFZ Innovation Award presented at this year's DKFZ annual reception, the association honored Titus Brinker as a researcher whose highly innovative work builds a bridge from research to practical application with commercialization potential.

HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds. The new funds of €15 million will be used to advance the clinical development of the clinical candidate HRX-215.

TWYCE GmbH - 10/07/2024

Better immune response against prostate cancer thanks to new bispecific antibodies

TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.

Freiburg-Prague research collaboration achieves scientific breakthrough in understanding cell division. The international research collaboration has uncovered a new mechanism of the crosstalk between microtubules and actin cytoskeleton during cell division and revealed unique characteristics of the previously unexplored protein FAM110A.

The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.

With "OrgaPlexing", scientists at the MPI of Immunobiology and Epigenetics have developed a new method that shows how guardian cells of the immune system, the macrophages, orchestrate their cell structures during inflammation or bacterial infection, making it possible to observe the interactions between several organelles simultaneously and thus providing insights into cell metabolism and the production of inflammatory molecules.

Scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD) have shown that the combination of therapeutic immune cells, known as CAR T cells, and a bispecific antibody could improve the treatment of leukaemia. In the culture dish and in mice, they tested CAR-T cells directed against the B-cell marker CD19 in combination with bispecific antibodies that bind to the B-cell-specific protein CD20.